Review
Copyright ©The Author(s) 2022.
World J Diabetes. Apr 15, 2022; 13(4): 282-307
Published online Apr 15, 2022. doi: 10.4239/wjd.v13.i4.282
Figure 1
Figure 1 Different lines for management of insulin resistance. DPP4: Dipeptidyl peptidase-4 inhibitors; GLP-1: Glucagon-like peptide-1; PPAR: Peroxisome proliferator-activated receptor; SNDRI: Serotonin-norepinephrine-dopamine reuptake inhibitor.